Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
Tri Juli Edi Tarigan,1 Adisti Dwijayanti,2 Susie Setyowati,3 Melva Louisa4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Department of Medical Pharmacy, F...
Enregistré dans:
Auteurs principaux: | Tarigan TJE, Dwijayanti A, Setyowati S, Louisa M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e27ef62c838e4bd0b2b40e3c8d590d0a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
par: L. N. Shitov, et autres
Publié: (2019) -
On the safety of insulin Glargine
par: Ivan Ivanovich Dedov, et autres
Publié: (2009) -
Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
par: Nader ND, et autres
Publié: (2020) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
par: Vadim Valer'evich Klimontov, et autres
Publié: (2014) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
par: Irina A. Proskurina, et autres
Publié: (2016)